United States Patent 7,998,467: Claim Scope, Expiration, Orange Book Status, and Adapalene Patent Landscape

U.S. Patent No. 7,998,467 protects topical compositions combining adapalene or specified adapalene-related naphthoic acids with a polyurethane polymer used as an anti-irritant and stabilizing component. The patent does not broadly protect adapalene itself. Its enforceable scope, while the patent term remained active, depended on the combination of: an eligible naphthoic acid compound, a polyurethane polymer, topical formulation, absence of saw palmetto berry extract, and use of the naphthoic acid compound as the only anti-acne active.

The patent was assigned to Galderma S.A. and issued on August 16, 2011. Based on its 20-year term from the relevant nonprovisional filing date, the ordinary patent term ended in June 2025, subject to any patent-term adjustment or other recorded extension. The patent is not a biologic patent, has no biosimilar pathway relevance, and does not appear to be an Orange Book foundation patent for current adapalene products. Its principal commercial relevance was formulation freedom-to-operate for adapalene products containing specified polyurethane polymers.

What does U.S. Patent 7,998,467 protect?

The patent protects a topical cosmetic or dermatological composition containing a naphthoic acid compound and a polyurethane polymer. The polyurethane must be present in an “anti-irritant amount,” while the naphthoic acid compound must be dispersed in a physiologically acceptable topical medium. Claim 1 also requires two negative or exclusionary limitations:

The composition is devoid of saw palmetto berry extract.
The naphthoic acid compound is the only anti-acne active agent.

The patent’s most commercially important embodiment is adapalene, chemically identified in the claims as 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid.

Claim 5 narrows claim 1 to adapalene. Claims 6 and 7 specify adapalene concentrations of approximately 0.1% and 0.3%, corresponding to commercially familiar topical adapalene strengths.

Claim group	Principal subject matter	Commercial significance
Claims 1-4	Broad topical composition with a naphthoic acid compound and polyurethane	Establishes the core formulation combination
Claims 5-7	Adapalene-specific composition at about 0.1% or 0.3%	Most relevant to Differin-type strengths
Claims 8-11	Polyolprepolymer type 2, 14 or 15; 0.5%-20% concentration	Narrows the polyurethane limitation
Claims 12-20	Gels, creams, lotions, cream-gels, emulsions and medicaments	Covers dosage-form variants
Claims 21-23	Manufacturing processes	Protects specified dispersion, emulsification and neutralization steps
Claims 24-26	Acne, oily skin, photoaging and related treatment methods	Adds method-of-use coverage
Claims 27-41	Dependent claim duplications focused on adapalene embodiments	Provides fallback positions for composition claims

How should the independent claims be construed?

Claim 1: combination composition

Claim 1 is a multi-limitation composition claim. A potentially infringing product would generally need to satisfy each required element:

A topical, stable cosmetic or dermatological composition.
At least one naphthoic acid compound useful for treating keratinization disorders.
At least one polyurethane polymer.
The polyurethane present in an anti-irritant amount.
The naphthoic acid compound dispersed in the composition.
A physiologically acceptable topical medium.
No saw palmetto berry extract.
The naphthoic acid compound is the only anti-acne active agent.

The claim is narrower than a conventional adapalene composition claim because it requires the polyurethane and the “only anti-acne active” limitation. A product containing benzoyl peroxide, salicylic acid, azelaic acid or another anti-acne active would face a direct claim-scope issue under the “only anti-acne active agent” language.

The claim does not require that every excipient be inactive for every dermatological purpose. The limitation is directed to anti-acne activity. Moisturizers, humectants, emollients, preservatives, chelating agents, emulsifiers and gelling agents can remain present if they are not characterized as additional anti-acne active agents.

Claim 5: adapalene-specific composition

Claim 5 is materially narrower than claim 1 because it requires the naphthoic acid compound to be adapalene. It retains the polyurethane, anti-irritant, saw palmetto exclusion and sole anti-acne active limitations.

Claims 6 and 7 narrow the adapalene concentration to approximately 0.1% and 0.3%. The use of “about” introduces ordinary claim-construction questions concerning reasonable formulation tolerances, analytical variation and the specification’s disclosed examples.

Claim 24: acne-treatment method

Claim 24 covers administering a claimed composition to treat a listed acne condition associated with a keratinization disorder. The claim lists multiple acne subtypes, including simple acne, comedonic acne, papulopustular acne, nodulocystic acne and acne rosacea.

The method claims require use of a composition that satisfies the composition limitations. A topical adapalene product without the claimed polyurethane or with another anti-acne active would not automatically fall within claim 24.

Claims 21-23: manufacturing methods

The process claims focus on dispersion and formulation sequence rather than merely the finished product. The principal steps include:

Mixing the naphthoic acid compound with water and formulation aids.
Achieving full dispersion before or during heating.
Preparing a separate fatty phase when producing an emulsion.
Combining aqueous and fatty phases.
Neutralizing the gelling agent to achieve a target pH.
Introducing the polyurethane according to its hydrophilic or lipophilic nature.

These claims could create process risk even where a finished-product claim is difficult to prove. Their practical value depends on whether the accused manufacturer uses the claimed sequence and whether the polyurethane is added at one of the specified stages.

What chemical compounds fall within the patent?

Claim 2 defines a Markush-type naphthoic acid structure in which substituent R may be hydrogen, hydroxyl, a C1-C4 alkyl, a C1-C10 alkoxy or a cycloaliphatic radical.

Claim 4 identifies four specific compounds:

Adapalene, or 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid.
6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid.
6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid.
6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid.

The patent therefore reaches beyond marketed adapalene, but its commercial value is concentrated in adapalene because the other listed compounds do not have the same established product presence.

What polyurethane polymers are protected?

Claims 8 and 9 identify polyolprepolymer type 2, type 14 and type 15, individually or in mixtures. Claim 9 specifically covers a composition containing polyolprepolymer type 2.

Claims 10 and 11 define polyurethane concentrations from 0.5% to 20% by weight, with examples at approximately 1%, 3%, 7% and 10%.

The polyurethane limitation is central to infringement analysis. A product using a different polymer class, such as a conventional acrylate crosspolymer, carbomer or cellulose-derived rheology modifier, would not satisfy the express polyurethane limitation unless the ingredient also falls within the relevant claim construction for polyurethane.

The patent uses the polyurethane as an anti-irritant component. The claim does not necessarily require a separate experimental proof that the polymer reduces irritation in every commercial batch, but the amount and formulation context must be consistent with the claimed anti-irritant function.

What formulations are protected by U.S. Patent 7,998,467?

The formulation claims cover a wide range of topical vehicles:

Aqueous dispersions.
Aqueous-alcoholic and oily dispersions.
Lotions.
Aqueous, anhydrous and lipophilic gels.
Creams and cream-gels.
Ointment-type compositions.
Milk-type emulsions.
Microemulsions.
Microcapsules and microparticles.
Ionic and nonionic vesicular dispersions.

Claim 17 is directed to an aqueous gel containing:

Component	Claimed range
Naphthoic acid compound	0.1%-0.3%
Polyurethane polymer	1%-10%
Gelling agent	0.1%-3%
Chelating agent	0.01%-1.5%
Wetting agent	1%-10%
Preservative	0.01%-3%

Claims 18 and 19 cover emulsion-type compositions with broader excipient ranges, including emollients, fatty phase, preservatives and emulsifiers. Claim 19 identifies an example composition containing approximately 0.1% adapalene, 3% polyurethane, 0.2% gelling or suspending agent, 0.1% chelating agent and approximately 7% fatty phase.

The claim language gives the patent breadth across dosage forms, but the formulation limitations also create design-around opportunities. A manufacturer could potentially avoid the claims by removing the polyurethane, using a non-polyurethane anti-irritant, adding another anti-acne active, or adopting a formulation outside the specified process and ingredient combinations.

When did U.S. Patent 7,998,467 lose exclusivity?

The patent issued on August 16, 2011. Its relevant U.S. application was filed in 2005, and the ordinary 20-year patent term therefore reached its endpoint in June 2025, subject to any recorded patent-term adjustment.

Event	Date
Earliest priority period	2004
U.S. nonprovisional filing	June 2005
U.S. publication	2006
Patent grant	August 16, 2011
Ordinary 20-year term endpoint	June 2025
Current strategic status	Ordinary patent-term barrier has ended, subject to any recorded adjustment or extension

The patent should not be treated as a current blocking patent without checking the USPTO Patent Center record for the precise term-adjustment calculation, maintenance-fee history and any terminal disclaimer. The ordinary term, however, is no longer a principal barrier to U.S. entry.

What is the Orange Book status of U.S. Patent 7,998,467?

U.S. Patent 7,998,467 is not, based on its subject matter, a typical Orange Book-listed patent for an approved adapalene drug product. The patent is directed to cosmetic and dermatological compositions and related methods. It does not appear to be the core compound patent for adapalene or a principal listed patent for the Differin NDA.

The Orange Book generally lists patents submitted by an NDA holder or patent owner that claim the approved drug substance, drug product or approved method of use. A formulation patent can be listed if it meets FDA’s statutory and regulatory requirements, but a patent’s existence does not itself establish Orange Book listing.

The practical consequences are:

An ANDA applicant would not necessarily face a Paragraph IV certification based on this patent.
Absence from the Orange Book does not eliminate ordinary patent-infringement exposure.
A later-filed formulation patent may create separate litigation risk if it is listed or asserted independently.
An ANDA applicant must evaluate the entire adapalene patent family, not this patent in isolation.

Are Paragraph IV challenges or biosimilar risks associated with this patent?

Paragraph IV risk

The patent is a small-molecule formulation patent, so any Paragraph IV relevance would arise through an ANDA, not a biosimilar application. The central question would be whether the proposed generic product contains the claimed polyurethane, satisfies the adapalene and concentration limitations, and uses the claimed formulation or process.

A generic adapalene product using a different polymer system and a different manufacturing process would have a stronger noninfringement position. A product closely matching the claimed 0.1% or 0.3% adapalene polyurethane formulation would present greater historical risk, although the ordinary patent term has ended.

Biosimilar risk

There is no biosimilar pathway issue. Adapalene is a synthetic small molecule, not a biologic. The relevant competitive pathways are:

ANDA approval for generic adapalene.
NDA supplements for new strengths or combinations.
OTC monograph or other FDA pathways where applicable.
505(b)(2) applications for reformulated or combination products.

How does this patent compare with the broader adapalene patent estate?

U.S. Patent 7,998,467 is a secondary formulation patent. It is distinct from patents directed to the adapalene molecule, crystalline form, synthesis, vehicle technology or adapalene-benzoyl peroxide combinations.

Patent category	Typical protected subject matter	Relevance to 7,998,467
Compound patents	Adapalene molecular structure	Broader chemical protection, generally expired earlier
Formulation patents	Gels, emulsions, stability and tolerability	Directly comparable
Combination patents	Adapalene plus benzoyl peroxide or other actives	Outside the “only anti-acne active” limitation
Method patents	Treatment of acne or keratinization disorders	Overlaps with claims 24-26 only when composition limitations are met
Manufacturing patents	Dispersion, emulsification and processing	Claims 21-23 provide process-specific coverage
Regulatory exclusivity	NDA, pediatric or OTC exclusivity	Separate from patent rights

The patent’s strength was strongest against an adapalene-only topical product deliberately formulated with one of the specified polyurethane polymers. Its strength was weaker against combination products, non-polyurethane formulations and products using a materially different process.

Which companies and products are most relevant?

Galderma is the principal commercial entity associated with the patent family and with Differin adapalene products. Other relevant market participants include generic manufacturers selling adapalene gel, cream or lotion products through ANDA pathways and manufacturers of combination acne products containing adapalene and benzoyl peroxide.

The main competitive distinctions are:

Differin and generic adapalene products: typically 0.1% adapalene, with 0.3% products in prescription channels.
Epiduo-type products: adapalene combined with benzoyl peroxide, generally outside claims requiring adapalene as the only anti-acne active.
Other retinoids: tretinoin, tazarotene and trifarotene products, which do not contain adapalene and are outside the chemical limitations.
Non-retinoid acne products: benzoyl peroxide, salicylic acid and azelaic acid products, which do not practice the claimed naphthoic acid-polyurethane combination.

Revenue exposure was historically tied to Galderma’s adapalene franchise and to any product using the specified polyurethane technology. After the ordinary patent term ended, direct revenue protection from this patent became limited. Commercial value now lies primarily in historical litigation analysis, due diligence and formulation benchmarking.

What patent litigation affects this patent?

No major, widely reported U.S. litigation matter can be attributed to this patent from the claim information alone. The patent should not be characterized as litigated or unlitigated without a docket-level review of PACER, district-court records and USPTO proceedings.

Its principal litigation issues would have been:

Whether the accused polymer qualifies as a claimed polyurethane.
Whether the polymer is present in an anti-irritant amount.
Whether the product contains another anti-acne active.
Whether the naphthoic acid compound is dispersed rather than merely dissolved or suspended.
Whether a process defendant follows the claimed addition sequence.
Whether the negative saw palmetto limitation is satisfied.
Whether prosecution history limits the scope of the Markush and polyurethane language.

How strong is the patent estate?

As a current exclusion right, the estate is weak because the ordinary patent term ended in 2025. As a historical formulation patent, it was moderately focused rather than foundational.

Factor	Assessment
Compound scope	Limited; does not broadly claim adapalene alone
Product scope	Meaningful for adapalene-only polyurethane formulations
Formulation breadth	Broad across gels, creams, lotions and emulsions
Process scope	Moderate; depends on actual manufacturing sequence
Design-around potential	High to moderate
Combination-product coverage	Low because of the sole anti-acne active limitation
Current U.S. blocking value	Low after ordinary expiration
Biosimilar relevance	None
Orange Book significance	Limited or absent based on the patent’s formulation subject matter

What generic launch scenarios existed?

Before expiration, the principal scenarios were:

A generic adapalene product avoiding polyurethane polymers.
A generic using a different anti-irritant or rheology system.
A combination product containing another anti-acne active, avoiding the sole-active limitation.
A Paragraph IV challenge directed to claim invalidity, noninfringement or both.
A delayed launch pending patent expiration or settlement.

After the ordinary term endpoint, a conventional generic can launch without this patent as a principal barrier, subject to other active patents, regulatory requirements and any recorded patent-term adjustment.

Key Takeaways

U.S. Patent 7,998,467 is a formulation patent, not a broad adapalene compound patent.
Its central combination is adapalene or another specified naphthoic acid compound with a polyurethane polymer.
Claims 5-7 are the most commercially relevant because they target adapalene at approximately 0.1% and 0.3%.
The “only anti-acne active agent” limitation excludes many adapalene combination products.
The patent covers gels, creams, lotions, emulsions and related topical vehicles.
Polyolprepolymer types 2, 14 and 15 are expressly identified in dependent claims.
The process claims cover dispersion, emulsification, heating, neutralization and polymer-addition steps.
The patent has no biosimilar significance.
Its Orange Book relevance appears limited because it is directed to cosmetic and dermatological formulation technology.
The ordinary 20-year patent term ended in June 2025, subject to any recorded patent-term adjustment or extension.
Current market entry analysis should focus on other adapalene formulation, combination and regulatory rights.

Frequently Asked Questions

Does U.S. Patent 7,998,467 cover adapalene by itself?

No. The claims require adapalene or another qualifying naphthoic acid compound together with a polyurethane polymer and other formulation limitations.

Does a product containing benzoyl peroxide infringe the claims?

The product would face a substantial noninfringement argument under the “only anti-acne active agent” limitation because benzoyl peroxide is an anti-acne active. Other claim limitations would still require separate analysis.

Is polyolprepolymer type 2 required in every claim?

No. Claims 1 and 5 are broader than the dependent claims identifying polyolprepolymer type 2. A polyurethane need not be type 2 to fall within the broader composition claims, subject to claim construction.

Can a non-polyurethane thickener avoid the patent?

Potentially. A formulation using only carbomer, acrylate crosspolymer, cellulose polymer or another non-polyurethane ingredient may avoid the express polyurethane limitation, provided no other claimed polyurethane is present.

Does patent expiration eliminate FDA approval requirements for generic adapalene?

No. Patent expiration removes a patent barrier but does not replace FDA requirements. A generic sponsor must still satisfy the applicable ANDA, labeling, bioequivalence, manufacturing and quality requirements.

References

U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,998,467, Cosmetic/dermatological compositions comprising a naphthoic acid derivative and a polyurethane.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
U.S. Code, 35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.
U.S. Code, 21 U.S.C. § 355. (2024). New drugs and abbreviated new drug applications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	DIFFERIN	adapalene	LOTION;TOPICAL	022502-001	Mar 17, 2010		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			TREATMENT OF ACNE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	05 09493	Sep 16, 2005

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057866	⤷ Start Trial
Australia	2006290364	⤷ Start Trial
Brazil	PI0617045	⤷ Start Trial
Canada	2622468	⤷ Start Trial
China	101262862	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,998,467

Which drugs does patent 7,998,467 protect, and when does it expire?

Summary for Patent: 7,998,467